Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Utidelone plus anlotinib for advanced NSCLC after standard treatment failure
ChiCTR2500115269Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2025
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
utideloneanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500115269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115269.